Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study Henderson, A, Paterson, DL, Chatfield, MD, Tambyah, PA, Lye, DC, De, PP, Lin, RTP, Chew, KL, Yin, M, Lee, TH, Yilmaz, M, Cakmak, R, Alenazi, TH, Arabi, YM, Falcone, M, Bassetti, M, Righi, E, Rogers, BA, Kanj, SS, Bhally, H, Iredell, J, Mendelson, M, Boyles, TH, Looke, DFM, Runnegar, NJ, Miyakis, S, Walls, G, Khamis, MAI, Zikri, A, Crowe, A, Ingram, PR, Daneman, N, Griffin, P, Athan, Eugene, Roberts, L, Beatson, SA, Peleg, AY, Cottrell, K, Bauer, MJ, Tan, E, Chaw, K, Nimmo, GR, Harris-Brown, T, Harris, PNA, MERINO Trial Investigators and Australasian Society for Infectious Disease Clinical Research Network (ASID-CDN) 2020, Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study, Clinical Infectious Diseases, pp. 1-9, doi: 10.1093/cid/ciaa1479. Attached Files Name Description MIMEType Size Downloads Title Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study Author(s) Henderson, A Paterson, DL Chatfield, MD Tambyah, PA Lye, DC De, PP Lin, RTP Chew, KL Yin, M Lee, TH Yilmaz, M Cakmak, R Alenazi, TH Arabi, YM Falcone, M Bassetti, M Righi, E Rogers, BA Kanj, SS Bhally, H Iredell, J Mendelson, M Boyles, TH Looke, DFM Runnegar, NJ Miyakis, S Walls, G Khamis, MAI Zikri, A Crowe, A Ingram, PR Daneman, N Griffin, P Athan, Eugene orcid.org/0000-0001-9838-6471 Roberts, L Beatson, SA Peleg, AY Cottrell, K Bauer, MJ Tan, E Chaw, K Nimmo, GR Harris-Brown, T Harris, PNA MERINO Trial Investigators Australasian Society for Infectious Disease Clinical Research Network (ASID-CDN) Journal name Clinical Infectious Diseases Start page 1 End page 9 Total pages 9 Publisher Oxford University Press Place of publication Oxford, Eng. Publication date 2020-10-27 ISSN 1058-4838 1537-6591 Keyword(s) Bloodstream infection Extended spectrum beta-lactamase Meropenem Piperacillin-tazobactam MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) Summary Abstract Introduction This study aims to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality in the MERINO trial. Methods Blood culture isolates from enrolled patients were tested by broth microdilution and whole genome sequencing at a central laboratory. Multivariate logistic regression was performed to account for confounders. Absolute risk increase for 30-day mortality between treatment groups was calculated for the primary analysis (PA) and the microbiologic assessable (MA) populations. Results In total, 320 isolates from 379 enrolled patients were available with susceptibility to piperacillin/tazobactam 94% and meropenem 100%. The piperacillin/tazobactam nonsusceptible breakpoint (MIC >16 mg/L) best predicted 30-day mortality after accounting for confounders (odds ratio 14.9, 95% confidence interval [CI] 2.8–87.2). The absolute risk increase for 30-day mortality for patients treated with piperacillin/tazobactam compared with meropenem was 9% (95% CI 3%–15%) and 8% (95% CI 2%–15%) for the original PA population and the post hoc MA populations, which reduced to 5% (95% CI −1% to 10%) after excluding strains with piperacillin/tazobactam MIC values >16 mg/L. Isolates coharboring extended spectrum β-lactamase (ESBL) and OXA-1 genes were associated with elevated piperacillin/tazobactam MICs and the highest risk increase in 30-day mortality of 14% (95% CI 2%–28%). Conclusions After excluding nonsusceptible strains, the 30-day mortality difference from the MERINO trial was less pronounced for piperacillin/tazobactam. Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA coharboring ESBLs suggests that meropenem remains the preferred choice for definitive treatment of ceftriaxone nonsusceptible Escherichia coli and Klebsiella. Notes In Press Language eng DOI 10.1093/cid/ciaa1479 Indigenous content off Field of Research 110399 Clinical Sciences not elsewhere classified 06 Biological Sciences 11 Medical and Health Sciences HERDC Research category C1 Refereed article in a scholarly journal Persistent URL http://hdl.handle.net/10536/DRO/DU:30147867 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 05 Feb 2021, 07:44:41 EST Sat, 06 Feb 2021, 04:01:16 EST Mon, 08 Feb 2021, 07:06:58 EST Fri, 05 Mar 2021, 05:03:59 EST Thu, 11 Mar 2021, 13:51:15 EST Thu, 11 Mar 2021, 13:55:34 EST Thu, 11 Mar 2021, 14:48:45 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 0 times in Scopus Search Google Scholar Access Statistics: 16 Abstract Views, 0 File Downloads  -  Detailed Statistics Created: Fri, 05 Feb 2021, 07:44:41 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.